Abstract
Recent studies have suggested that metformin (MF) may lower thyrotropin concentration. This suggests a possible need for a dose reduction of levothyroxine in hypothyroid patients taking MF. However, contradictory results from heterogeneous study populations indicate that the underlying causes have not been completely elucidated. Patients with postoperative hypothyroidism-a condition not influenced by endogenous thyroid hormone production-have not been evaluated in order to evaluate the impact of MF. To determine the impact of MF in total thyroidectomized patients receiving levothyroxine replacement. One hundred ninety-two patients underwent total thyroidectomy during three years and were receiving levothyroxine substitution. Patients were divided into two groups depending on MF use: the non-MF group included 159 patients, of whom 134 were women [mean (SD) age, 52 (15.7) years; mean (SD) body weight, 70.2 (13.5) kg; 56 with differentiated thyroid cancer]; the MF group comprised 33 patients, of whom 24 were women [mean (SD) age, 63 (9.8) years; mean (SD) body weight, 79.3 (13.9) kg; 9 with differentiated thyroid cancer]. Levothyroxine requirements were compared between the groups, and the differentiated thyroid cancer cases were also analyzed separately. Thyrotropin levels did not differ significantly between the MF and the non-MF groups. No differences in total levothyroxine dosage were found: 114 (100-150) [median (Q1-Q3)] μg in the non-MF group versus 125 (100-142) μg in the MF group (p=0.9). When calculating the weight-adjusted levothyroxine dose, significant differences were evident: 1.66 (1.38-2.08) μg/kg in the non-MF group versus 1.53 (1.26-1.70) μg/kg in the MF group (p=0.010). However, in a multivariate regression model with thyrotropin levels, age, body mass index, sex, and type of thyroid disease, MF treatment lost its significance. Thyroidectomized patients receiving MF treatment need a lower thyroxine dose than patients who do not receive the drug, possibly due to different characteristics (greater weight, age) of the patients with diabetes mellitus type 2.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.